JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma

  • 0Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College, Nanchong City, Sichuan Province, China.
Clinics +

|

May 11, 2024

|

May 11, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Apatinib combined with Temozolomide (TMZ) effectively treats recurrent Glioblastoma (GB) by reducing soluble PD-1 (sPD-1) and sPD-L1 levels. This combination therapy improves patient survival and remission rates with manageable side effects.

Area Of Science

  • Oncology
  • Immunotherapy
  • Pharmacology

Background

  • Recurrent Glioblastoma (GB) presents significant treatment challenges.
  • Drug resistance limits therapeutic options for recurrent GB.
  • Targeting immune checkpoints like PD-1/PD-L1 is a promising strategy.

Purpose Of The Study

  • To evaluate the efficacy of Apatinib plus Temozolomide (TMZ) in drug-resistant recurrent GB.
  • To assess the impact of this combination on Soluble PD-1 (sPD-1) and Soluble Programmed Death-1 Ligand (sPD-L1) levels.
  • To compare clinical outcomes and safety profiles between the combination therapy and TMZ alone.

Main Methods

  • A prospective study involving 69 patients with recurrent GB.
  • Patients were randomized into a control group (TMZ) and an observation group (Apatinib + TMZ).
  • Key endpoints included sPD-1, sPD-L1 levels, objective remission rate, survival times, and adverse events.

Main Results

  • The Apatinib + TMZ group showed significant reductions in sPD-1 and sPD-L1 levels post-treatment.
  • Higher objective remission and clinical benefit rates were observed in the combination group.
  • Overall survival and progression-free survival were significantly longer in the observation group compared to the control group.
  • No significant differences in major adverse reactions were noted between the groups.

Conclusions

  • Apatinib combined with TMZ is a safe and effective treatment for recurrent Glioblastoma.
  • This combination therapy demonstrates potential by decreasing sPD-1 and sPD-L1 levels.
  • The findings support the clinical utility of Apatinib + TMZ in managing drug-resistant recurrent GB.

Keywords: